KRYS
Price
$173.16
Change
-$7.84 (-4.33%)
Updated
Apr 3, 02:47 PM (EDT)
Capitalization
5.21B
39 days until earnings call
MRUS
Price
$42.52
Change
-$0.49 (-1.14%)
Updated
Apr 3, 02:50 PM (EDT)
Capitalization
2.97B
40 days until earnings call
Ad is loading...

KRYS vs MRUS

Header iconKRYS vs MRUS Comparison
Open Charts KRYS vs MRUSBanner chart's image
Krystal Biotech
Price$173.16
Change-$7.84 (-4.33%)
Volume$100
Capitalization5.21B
Merus
Price$42.52
Change-$0.49 (-1.14%)
Volume$700
Capitalization2.97B
KRYS vs MRUS Comparison Chart
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. MRUS commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Hold and MRUS is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (KRYS: $181.00 vs. MRUS: $43.01)
Brand notoriety: KRYS and MRUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 89% vs. MRUS: 125%
Market capitalization -- KRYS: $5.21B vs. MRUS: $2.97B
KRYS [@Biotechnology] is valued at $5.21B. MRUS’s [@Biotechnology] market capitalization is $2.97B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 1 FA rating(s) are green whileMRUS’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 1 green, 4 red.
  • MRUS’s FA Score: 1 green, 4 red.
According to our system of comparison, both KRYS and MRUS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 3 TA indicator(s) are bullish while MRUS’s TA Score has 5 bullish TA indicator(s).

  • KRYS’s TA Score: 3 bullish, 5 bearish.
  • MRUS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MRUS is a better buy in the short-term than KRYS.

Price Growth

KRYS (@Biotechnology) experienced а -3.26% price change this week, while MRUS (@Biotechnology) price change was -3.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.69%. For the same industry, the average monthly price growth was -9.74%, and the average quarterly price growth was -14.08%.

Reported Earning Dates

KRYS is expected to report earnings on May 12, 2025.

MRUS is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-7.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($5.21B) has a higher market cap than MRUS($2.97B). KRYS YTD gains are higher at: 15.537 vs. MRUS (2.283). KRYS has higher annual earnings (EBITDA): 110M vs. MRUS (-269.6M). KRYS has more cash in the bank: 598M vs. MRUS (537M). KRYS has less debt than MRUS: KRYS (7.26M) vs MRUS (9.91M). KRYS has higher revenues than MRUS: KRYS (291M) vs MRUS (36.1M).
KRYSMRUSKRYS / MRUS
Capitalization5.21B2.97B175%
EBITDA110M-269.6M-41%
Gain YTD15.5372.283681%
P/E Ratio58.19N/A-
Revenue291M36.1M806%
Total Cash598M537M111%
Total Debt7.26M9.91M73%
FUNDAMENTALS RATINGS
KRYS vs MRUS: Fundamental Ratings
KRYS
MRUS
OUTLOOK RATING
1..100
7866
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
61
Fair valued
PROFIT vs RISK RATING
1..100
1829
SMR RATING
1..100
6897
PRICE GROWTH RATING
1..100
5179
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRUS's Valuation (61) in the Biotechnology industry is in the same range as KRYS (79) in the Pharmaceuticals Major industry. This means that MRUS’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (18) in the Pharmaceuticals Major industry is in the same range as MRUS (29) in the Biotechnology industry. This means that KRYS’s stock grew similarly to MRUS’s over the last 12 months.

KRYS's SMR Rating (68) in the Pharmaceuticals Major industry is in the same range as MRUS (97) in the Biotechnology industry. This means that KRYS’s stock grew similarly to MRUS’s over the last 12 months.

KRYS's Price Growth Rating (51) in the Pharmaceuticals Major industry is in the same range as MRUS (79) in the Biotechnology industry. This means that KRYS’s stock grew similarly to MRUS’s over the last 12 months.

KRYS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as MRUS (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to MRUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSMRUS
RSI
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
89%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
73%
MACD
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 16 days ago
76%
Bullish Trend 15 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 3 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Ad is loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MDYG81.581.55
+1.94%
SPDR® S&P 400 Mid Cap Growth ETF
WOMN38.500.24
+0.63%
Impact Shares YWCA Women's Empwrmt ETF
SEA12.620.01
+0.08%
US Global Sea to Sky Cargo ETF
IJAN32.00N/A
+0.01%
Innovator Itnl Dvp Pwr Buff ETF™ Jan
TAXF49.50-0.12
-0.24%
American Century Divers Muncpl Bd ETF

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with IDYA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+3.68%
IDYA - KRYS
51%
Loosely correlated
+10.70%
ACLX - KRYS
48%
Loosely correlated
+10.76%
CRNX - KRYS
48%
Loosely correlated
+2.51%
ZLDPF - KRYS
45%
Loosely correlated
+0.22%
PRME - KRYS
45%
Loosely correlated
+0.28%
More

MRUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRUS has been loosely correlated with CYTK. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if MRUS jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRUS
1D Price
Change %
MRUS100%
+8.61%
CYTK - MRUS
35%
Loosely correlated
+7.33%
KRYS - MRUS
34%
Loosely correlated
+3.68%
CGON - MRUS
34%
Loosely correlated
+0.86%
VCYT - MRUS
34%
Loosely correlated
+1.93%
XENE - MRUS
33%
Loosely correlated
+2.68%
More